Last 1,208
Change Today 0.00 / 0.00%
Volume 0.0
PSTI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
Tel Aviv
As of 10:24 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Open
$1,218
Previous Close
$1,205
Day High
$1,224
Day Low
$1,200
52 Week High
03/6/14 - $1,520
52 Week Low
08/14/14 - $909.10
Market Cap
852.0M
Average Volume 10 Days
304.3K
EPS TTM
$-0.41
Shares Outstanding
70.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PLURISTEM THERAPEUTICS INC (PSTI)

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

160 Employees
Last Reported Date: 09/11/14
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $503.7K
President and Chief Operating Officer
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2014.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem Therapeutics Inc. Announces the Positive Results of Trial Conducted by the U.S. National Institutes of Health (NIH) to Evaluate PLX-R18 Cells

Pluristem Therapeutics Inc. announced the positive results of a recently completed trial conducted by the U.S. National Institutes of Health (NIH) to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster. Injection of PLX-R18 cells into muscle, as compared to a placebo, resulted in a statistically significant improvement in the recovery of white blood cell, red blood cell, and platelet levels in animals exposed to high levels of radiation. The data also suggested that the treatment may potentially be able to shorten time to recovery. High levels of radiation can destroy the body's ability to produce these three blood lineages, and rapidly regaining that capacity is a key factor in surviving the hematologic component of acute radiation syndrome (ARS), a condition caused by high-dose irradiation that can involve severe, sometimes lethal damage to the bone marrow as well as other physiologic systems and organs. The objective of this latest trial was to investigate the mechanism of action behind the significant improvement in survival in irradiated mice treated with PLX-R18 that was demonstrated in the NIH's first efficacy study. The results of the current study indicate that intramuscular administration exerts a systemic healing effect on bone marrow, lending further support to the concept that Pluristem's cells work systemically via secretion of therapeutic proteins, although the cells themselves remain in the muscle into which they were initially injected. While additional animal trials are needed prior to U.S. Food and Drug Administration (FDA) approval of PLX-R18 for use in ARS, no human trials would be required because product development is conducted under the FDA's Animal Rule. Pluristem is developing PLX-R18 cells for other potential indications including enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency. Trials for this indication are ongoing at Case Western University and Hadassah Medical Center. Data from the NIH studies in ARS are expected to benefit Pluristem's development of its hematology program.

Pluristem Announces Encouraging Data from Phase I/II Muscle Injury Trial

Pluristem Therapeutics, Inc. has announced new data from its Phase I/II clinical trial of PLacental eXpanded, or PLX-PAD, cells in the treatment of muscle injury after total hip arthroplasty, or THA. Data showed that six months after surgery the magnitude of improvement in muscle force of the contralateral (non-operated) gluteal muscle was approximately 40 times larger in patients treated with 150 million PLX-PAD cells than in those who received placebo, and the difference was statistically significant (19.4 vs 0.5 Nm, p=0.0114). Patients treated with 300 million PLX-PAD cells also showed a larger increase in muscle force than patients injected with placebo (9.48 vs 0.46 Nm, p=0.227). Pluristem further announced positive twelve-month safety data from the trial. These findings follow the January 21, 2014 announcement that the study had met its primary efficacy and safety endpoints. The primary efficacy finding was the change in maximal voluntary isometric contraction force of the gluteal muscle in the operated leg at six months after total hip replacement. There was a large and statistically significant improvement in patients who were injected with 150 million cells versus those who received placebo (31.1 vs 5.4 Nm, p=0.0067).

Pluristem Therapeutics Inc. Announces Study Results of PLacental eXpanded (PLX) Cells

Pluristem Therapeutics Inc. announced that a study of PLacental eXpanded (PLX) cells was accepted for publication in the February, 2015 issue of Biochimica et Biophysica Acta [2]Molecular Cell Research. The study results show that PLX cells protect PC12 cells - an established model of various nerve cells including dopaminergic neurons from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:IT 1,208.00 0.00

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.59 USD +0.02
Cytori Therapeutics Inc $1.12 USD -0.01
NeoStem Inc $3.76 USD -0.07
Ocata Therapeutics Inc $7.22 USD -0.03
StemCells Inc $1.12 USD +0.03
View Industry Companies
 

Industry Analysis

PSTI

Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 563.9x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 448.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit www.pluristem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.